索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 研究圣经
  • 中国知网(CNKI)
  • 西马戈
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 米亚尔
  • 科学索引服务 (SIS)
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Functionalization of Iron Oxide Magnetic Nanoparticles with the Multivalent Pseudopeptide N6l for Breast Tumor Targeting

Maha Sader, Pierre Couleaud, Gilles Carpentier, Maud-Emmanuelle Gilles, Noureddine Bousserrhine, Alexandre Livet, Ilaria Cascone, Damien Destouches, Aitziber L Cortajarena and José Courty

Functionalized iron oxide magnetic nanoparticles (MNP) are an innovative tool for cancer detection and treatment. In this study, a cell-surface nucleolin antagonist, N6L, was used as targeting ligand for MNP. This N6L, which exhibits antitumor activities, specifically targets bind tumor cells by binding to cell-surface nucleolin and glycosaminoglycans. N6L was covalently conjugated to dimercaptosuccinic acid coated magnetic nanoparticles (MNP-N6L). Using immunoprecipitation, gene invalidation and enzymatic degradation of glycosaminoglycans, we showed that MNP-N6L targets human breast cancer MDA-MB 231 cells through interaction with nucleolin and sulfated glycosaminoglycans. In vivo biodistribution studies were carried out in MDA-MB 231 tumor-bearing mice, using iron detection assay by spectrometric analysis and Prussian blue staining. Whereas both non-functionalized and functionalized nanoparticles were found in liver and spleen, only MNP-N6L was found in the tumor. Our findings indicate that MNP-N6L is a promising targeting system for theranostic applications in cancer detection and treatment.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证